-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

652.O1.6 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL Amyloidosis

Symposia: MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Translational Research, Epidemiology, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Immunotherapy, Biological therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, Measurable Residual Disease
Monday, December 9, 2024: 2:45 PM-4:15 PM
Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)
Moderators:
Meral Beksac, MD, Istinye University Ankara Liv Hospital and Naresh Bumma, MD, Ohio State University/James Cancer Center
Disclosures:
Beksac: GSK: Research Funding; Amgen: Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees; Sanofi: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau; Janssen: Research Funding, Speakers Bureau. Bumma: Janssen: Consultancy.

AL Amyloidosis is a rare plasma cell disorders which is gaining importance as both both awareness, knowledge on genetic background  and treatment options are  increasing. In this session novel treatment options, novel risk classification approaches and importance of depth of response will be presented.
2:45 PM

Marta Lasa1*, Mario Nuvolone, MD, PhD2,3*, Ioannis V Kostopoulos, PhD4*, Tomas Jelinek, MD, PhD5*, Marco Basset, MD, PhD3*, Paolo Milani, MD, PhD6,7, Margherita Massa, PhD8*, Foteini Theodorakakou, MD9*, Ashutosh D. Wechalekar, MBBS, DM, FRCP, FRCPath10,11,12, Anastasiia Zherniakova, MD, PhD13*, Rafael Ríos, MD, PhD14*, Irene Romera15*, Maria Teresa Cedena Romero, MD, PhD16*, Noemi Puig, PhD17, Ramon Lecumberri Villamediana, MD, PhD18*, Jesús F. San-Miguel, MD, PhD19, Roman Hajek, MD, PhD20, Giampaolo Merlini, MD, PhD3,21*, Efstathios Kastritis, MD, PhD9*, Bruno Paiva, PhD22* and Giovanni O. Palladini, MD, PhD23

1Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBER-ONC number CB16/12/00369, Pamplona, Spain
2Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Pavia, Pavia, Italy, Pavia, Italy
3Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
4Department of Biology, School of Science, National and Kapodistrian University of Athens (NKUA), Athens, Greece
5Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
6Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo," and Department of Molecular Medicine, University of Pavia, Pavia, Italy
7Foundation IRCCS Policlinico San Matteo, Pavia, Italy
8IRCCS Policlinico S. Matteo Foundation, Pavia, ITA
9Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
10Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
11Royal Free London Hospital, National Amyloid Centre, London, United Kingdom
12University College London Hospital, London, United Kingdom
13Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russian Federation
14Hospital Universitario Virgen De Las Nieves, Granada, ESP
15Department of Hematology, Hospital Universitario Puerta de Hierro, Majadahonda, AL, Spain
16Instituto de Investigación IMAS12, Madrid, Spain
17Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain
18Hematology and Cell Therapy Department. Clinica Universidad de Navarra, Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain
19Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBER-ONC CB16/12/00369, Pamplona, Spain, Pamplona, Spain
20University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic
21University of Pavia, Pavia, ITA
22Department of Hematology, Centre for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Pamplona, Spain
23Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo," and Department of Molecular Medicine, University of Pavia, Pavia, PV, Italy

3:00 PM

Jahanzaib Khwaja1,2, Sriram Ravichandran1*, Joshua Bomsztyk2*, Oliver Charles Cohen2*, Darren Foard2*, Ana Martinez-Naharro2*, Lucia Venneri2*, Marianna Fontana2*, Carol Whelan2*, Philip N Hawkins2*, Julian Gillmore2*, Helen J Lachmann2*, Shameem Mahmood2*, Amy A Kirkwood, MSc3* and Ashutosh D. Wechalekar, MBBS, DM, FRCP, FRCPath1,2

1University College London Hospital, London, United Kingdom
2Royal Free London Hospital, National Amyloid Centre, London, United Kingdom
3Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, United Kingdom

3:15 PM

Efstathios Kastritis, MD1*, Giovanni O. Palladini, MD, PhD2, Monique C. Minnema3, Ashutosh D. Wechalekar, MBBS, DM, FRCP, FRCPath4, Arnaud Jaccard, MD, PhD5*, Hans C. Lee, MD6, Vaishali Sanchorawala7, Peter Mollee, FRACP, MBBS, MSc, FRCPA8, Jin Lu9*, Stefan Schönland10*, Moshe E Gatt, MD11, Kenshi Suzuki, MD, PhD12, Kihyun Kim, MD13*, M. Teresa Cibeira, MD, PhD14*, Manisha Bhutani, MD15, Meral Beksac16*, Edward Libby, MD17, Jason Valent, MD18, Vania Hungria, MD, PhD19, Michael Rosenzweig, MD20, Naresh Bumma, MD21, Antoine Huart, MD22*, NamPhuong Tran23*, Jianping Wang24*, Yuping Chen25*, Sandra Y. Vasey26*, Jordan M. Schecter24, Jessica Vermeulen, MD, PhD27, Raymond L. Comenzo28* and Giampaolo Merlini, MD, PhD2*

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Voula,Athens, AL, Greece
2Department of Molecular Medicine, University of Pavia, Pavia, Italy
3Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, Netherlands
4University College London, London, United Kingdom
5Reference Center for AL Amyloidosis, Limoges, France
6Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
7Amyloidosis Center, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, Boston, MA
8Department of Haematology, Princess Alexandra Hospital and University of Queensland Medical School, Brisbane, Australia
9Peking University Institute of Hematology, Peking University Peoples’ Hospital, Beijing, China
10Universitaetsklinikum Heidelberg Medizinische Klinik V, Heidelberg, Germany
11Hadassah Medical Center, Jerusalem, Israel
12Japanese Red Cross Central Medical Center, Shibuya, Tokyo, Japan
13Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Republic of (South)
14Hospital Clinic of Barcelona, Barcelona, Spain
15Department of Hematologic Oncology and Blood Disorders, Atrium Health/Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC
16Ankara Liv Hospital, Istinye University, Ankara, Turkey
17Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
18Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
19Clinica São Germano, São Paulo, Brazil
20Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA
21Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
22CHU Rangueil, Toulouse, France
23Janssen Research & Development, LLC, Los Angeles, CA
24Janssen Research & Development, LLC, Raritan, NJ
25Janssen Research & Development, LLC, Shanghai, China
26Janssen Research & Development, LLC, Spring House, PA
27Janssen Research & Development, LLC, Leiden, Netherlands
28John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

3:30 PM

Peter Mollee, FRACP, MBBS, MSc, FRCPA1, Antoine Huart, MD2*, Olga Mortona, MBBS BA BCh BAO FRACP FRCPA3*, Kentin Queru, MD4*, Cecile Leyronnas, MD5*, Harel Stephanie, MD6*, Hasib Sidiqi, MBBS, FRACP, FRCPA7*, Estelle Desport, MD8*, Laure Vincent, MD9*, Margaret Macro, MD10*, Salomon Manier, MD, PhD11, Caroline Jacquet, MD12*, Pierre Morel, MD, PhD13*, Noemi Horvath14, Sebastien Bender, PhD15,16*, Guillaume Olombel, MD15*, Virginie Pascal, MD, PhD16*, Jill Corre, PharmD, PhD17*, Frank Bridoux, MD, PhD8*, Arnaud Jaccard, MD, PhD4* and Murielle Roussel, MD18*

1Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia
2Department of Nephrology and Organs Transplantation, CHU de Toulouse Rangueil, Toulouse, France
3Eastern Haematology Oncology Group, Austin Hospital, Monash Health and Eastern Health, Box Hill VIC 3128, Australia
4Hématologie Clinique, CHU de Limoges, Limoges, France
5Hématologie, CHU de Grenoble, Grenoble, FRA
6Department of Immuno-hematology,, Saint Louis Hospital, APHP, Paris, France
7Fiona Stanley Hospital, Southbank, Australia
8Néphrologie, CHU de Poitiers, Poitiers, France
9Department of Clinical Hematology, Hôpital St Eloi, CHU de Montpellier, Montpellier, France
10Hopital Cote De Nacre, Caen, France
11Centre Hospitalier Universitaire - Hôpital Huriez, Lille, France
12CHU de Nancy, Vandoeuvre Les Nancy, FRA
13Service d’Hématologie Clinique, Centre Hospitalier Universitaire Amiens-Picardie, Salouel, France
14Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, Australia
15Immunologie, CHU de Limoges, Limoges, France
16CNRS UMR 7276, INSERM UMR 1262, Université de Limoges, Limoges, France
17Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
18Hématologie Clinique, CHU de Limoges, Limoges Cedex 1, France

3:45 PM

Kaini Shen, MD1*, Ai Guan, MD2*, Yu Wu, MD3, Chunyan Sun4*, Liye Zhong, MD, PhD5*, Jun Luo, MD6* and Jian Li, MD7

1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHN
2Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
4Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5Guangdong Provinal People's Hospital, Guangzhou, China
6Department of Haematology, THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY, Nanning, China
7Department of Hematology, Peking Union Medical College Hospital, Beijing, China

4:00 PM

Eyal Lebel1*, Nathalie Asherie1,2*, Miri Assayag1,2*, Shlomo Elias, MD, PhD1,2, Sigal Grisariu, MD1,2*, Batia Avni, MD1,2*, Shlomit Kfir-Erenfeld1,2*, Tali Dubnikov-Sharon1*, Rivka Alexander-Shani1*, Nomi Bessig1*, Alaa Shehadeh1*, Aseel Ishtay1*, Shelly Pimienta1*, Vladimir Vaistein2,3*, Eran Zimran1,4*, Marjorie Pick3*, Yael C. Cohen5,6, Irit Avivi Mazza5,6*, Cyrille Cohen7*, Polina Stepensky1,8* and Moshe E Gatt, MD2,3

1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem, Israel
2Faculty of Medicine, The Hebrew University, Jerusalem, Israel
3Department of Hematology, Hadassah Medical Center, Jerusalem, Israel
4Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
5Department of Hematology, Tel Aviv Medical Center, Tel Aviv, Israel
6Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
7Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel
8Hadassah University Hospital, Jerusalem, Israel

*signifies non-member of ASH